A novel tuberculosis DNA vaccine in an HIV-1 p24 protein backbone confers protection against Mycobacterium tuberculosis and simultaneously elicits robust humoral and cellular responses to HIV-1

Clinical and Vaccine Immunology

Volumn 19, Issue 5, 2012, Pages 723-730

  Li, Xiaoman ^a   Xu, Wei ^b   Xiong, Sidong ^a,b  

^a FUDAN UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; BCG VACCINE; DNA VACCINE; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; BCG VACCINATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SPECIFICITY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; LUNG INJURY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; T LYMPHOCYTE; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL LOAD; CELL PROLIFERATION; CYTOTOXICITY TESTS, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; HIV ANTIBODIES; HIV CORE PROTEIN P24; HUMANS; INTERFERON-GAMMA; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTES; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, DNA;

EID: 84860347509     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05700-11     Document Type: Article

References (45)

1. Al-Attiyah R, Mustafa AS. 2008. Characterization of human cellular immune responses to novel Mycobacterium tuberculosis antigens encoded by genomic regions absent in Mycobacterium bovis BCG. Infect. Immun. 76:4190-4198.
2. Ametani A, et al. 2003. Amino acid residue substitution at T-cell determinant-flanking sites in beta-lactoglobulin modulates antigen presentation to T cells through subtle conformational change. Biosci. Biotechnol. Biochem. 67:1507-1514. (Pubitemid 39251788)
3. Ammaranond P, et al. 2011. HIV immune escape at an immunodominant epitope in HLA-B*27-positive individuals predicts viral load outcome. J. Immunol. 186:479-488.
4. Barouch DH. 2008. Challenges in the development of an HIV-1 vaccine. Nature 455:613-619.
5. Capozzo AV, et al. 2006. Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cellmediated immunity in the presence of maternal antibodies. J. Immunol. 176:5671-5681.
6. Chan J, Flynn J. 2004. The immunological aspects of latency in tuberculosis. Clin. Immunol. 110:2-12. (Pubitemid 38177416)
7. Chapman AL. 2011. New tests will improve detection of latent TB. Practitioner 255(1745):23-26.
8. Chen L, Wang J, Zganiacz A, Xing Z. 2004. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun. 72:238-246. (Pubitemid 38018181)
9. Culshaw A, Dong T, Rowland-Jones SL. 2012. A two amino acid shift in position leads to a substantial difference in the pattern of processing of two HIV-1 epitopes. J. Acquir. Immune Defic. Syndr. 59:335-339.
10. Depla E, et al. 2008. Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J. Virol. 82:435-450. (Pubitemid 350309158)
11. D'Souza S, et al. 2003. Mapping of murine Th1 helper T-cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect. Immun. 71:483-493. (Pubitemid 36026053)
12. Fallahi-Sichani M, Flynn JL, Linderman JJ, Kirschner DE. 2012. Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. J. Immunol. 188:3169-3178.
13. Fernandez-Carneado J, et al. 2000. Surface grafting onto templateassembled synthetic protein scaffolds in molecular recognition. Biopolymers 55:451-458. (Pubitemid 32493243)
14. Gao L, Zhou F, Li X, Jin Q. 2010. HIV/TB co-infection in mainland China: A meta-analysis. PLoS One 5:e10736.
15. Gong X, Gai W, Xu J, Zhou W, Tien P. 2009. Glycoprotein 96-mediated presentation of human immunodeficiency virus type 1 (HIV-1)-specific human leukocyte antigen class I-restricted peptide and humoral immune responses to HIV-1 p24. Clin. Vaccine Immunol. 16:1595-1600.
16. Harrington M. 2010. From HIV to tuberculosis and back again: A tale of activism in 2 pandemics. Clin. Infect. Dis. 50(Suppl. 3):S260-S266.
17. Hart MK, et al. 1990. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. J. Immunol. 145:2677-2685. (Pubitemid 20374595)
18. Huygen K, et al. 1996. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat. Med. 2:893-898. (Pubitemid 26296760)
19. Im EJ, et al. 2007. Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J. Virol. 81:9408-9418.
20. Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ. 1999. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect. Immun. 67:1702-1707. (Pubitemid 29144386)
21. Korber B, LaBute M, Yusim K. 2006. Immunoinformatics comes of age. PLoS Comput. Biol. 2:e71.
22. Launois P, et al. 1994. T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infect. Immun. 62:3679-3687. (Pubitemid 24264307)
23. Lawn SD, Churchyard G. 2009. Epidemiology of HIV-associated tuberculosis. Curr. Opin. HIV AIDS 4:325-333.
24. Letvin NL. 2007. Correlates of immune protection and the development of a human immunodeficiency virus vaccine. Immunity 27:366-369. (Pubitemid 47418683)
25. Leversen NA, Sviland L, Wiker HG, Mustafa T. 12 January 2012. Long-term persistence ofBCGPasteur in lungs of C57BL/6 mice following intranasal infection. Scand. J. Immunol. doi:10.1111/j.1365-3083.2012.02683.x. [Epub ahead of print.
26. Maartens G, Wilkinson RJ. 2007. Tuberculosis. Lancet 370:2030-2043. (Pubitemid 350236315)
27. Mateu MG. 2009. The capsid protein of human immunodeficiency virus: Intersubunit interactions during virus assembly. FEBS J. 276:6098-6109.
28. Meya DB, McAdam KP. 2007. The TB pandemic: An old problem seeking new solutions. J. Intern. Med. 261:309-329. (Pubitemid 46474764)
29. Ministry of Health. 1998. Care and use of laboratory animals, no. 55. Ministry of Health, Beijing, People's Republic of China
30. Ofek G, et al. 2010. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl. Acad. Sci. U. S. A. 107:17880-17887.
31. Okazaki T, et al. 2006. Epitope enhancement of a CD4 HIV epitope toward the development of the next generation HIV vaccine. J. Immunol. 176:3753-3759. (Pubitemid 43364022)
32. Parvanova I, Rettig L, Knuth A, Pascolo S. 2011. The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination. Vaccine 29:3832-3836.
33. Prabhu Anand S, Selvaraj P, Narayanan PR. 2009. Effect of 1,25 dihydroxyvitamin D3 on intracellular IFN-gamma and TNF-alpha positive T cell subsets in pulmonary tuberculosis. Cytokine 45:105-110.
34. Raby E, et al. 2008. The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis. PLoS One 3:e2489.
35. + T cell responses. PLoS One 6:e16921.
36. Skjot RL, et al. 2002. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect. Immun. 70:5446-5453.
37. Song S, et al. 2007. Evaluation of antitumor immunity efficacy of epitopebased vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice. Vaccine 25:4853-4860. (Pubitemid 46818610)
38. Sterne JA, Rodrigues LC, Guedes IN. 1998. Does the efficacy of BCG decline with time since vaccination. Int. J. Tuberc. Lung Dis. 2:200-207. (Pubitemid 28123518)
39. Tanghe A, et al. 1999. Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors. J. Immunol. 162:1113-1119. (Pubitemid 29035442)
40. Tissot AC, et al. 2010. Versatile virus-like particle carrier for epitope based vaccines. PLoS One 5:e9809.
41. Townsend AR, et al. 1986. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44:959-968. (Pubitemid 16045342)
42. + T cell response. J. Immunol. 186:359-371.
43. Wang C, et al. 2011. A DNA vaccine expressing CFP21 and MPT64 fusion protein enhances BCG-induced protective immunity against Mycobacterium tuberculosis infection in mice. Med. Microbiol. Immunol. 200:165-175.
44. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. 2008. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med. 14:617-621. (Pubitemid 351809543)
45. WHO. 2010. Global tuberculosis control. WHO, Geneva, Switzerland.